GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » TSH Biopharm Corp Ltd (ROCO:8432) » Definitions » Cyclically Adjusted PB Ratio

TSH Biopharm (ROCO:8432) Cyclically Adjusted PB Ratio : 1.37 (As of May. 04, 2025)


View and export this data going back to 2012. Start your Free Trial

What is TSH Biopharm Cyclically Adjusted PB Ratio?

As of today (2025-05-04), TSH Biopharm's current share price is NT$49.90. TSH Biopharm's Cyclically Adjusted Book per Share for the quarter that ended in Dec. 2024 was NT$36.30. TSH Biopharm's Cyclically Adjusted PB Ratio for today is 1.37.

The historical rank and industry rank for TSH Biopharm's Cyclically Adjusted PB Ratio or its related term are showing as below:

ROCO:8432' s Cyclically Adjusted PB Ratio Range Over the Past 10 Years
Min: 1.13   Med: 1.39   Max: 2.31
Current: 1.3

During the past years, TSH Biopharm's highest Cyclically Adjusted PB Ratio was 2.31. The lowest was 1.13. And the median was 1.39.

ROCO:8432's Cyclically Adjusted PB Ratio is ranked better than
60.92% of 632 companies
in the Drug Manufacturers industry
Industry Median: 1.67 vs ROCO:8432: 1.30

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

TSH Biopharm's adjusted book value per share data for the three months ended in Dec. 2024 was NT$36.246. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is NT$36.30 for the trailing ten years ended in Dec. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


TSH Biopharm Cyclically Adjusted PB Ratio Historical Data

The historical data trend for TSH Biopharm's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

TSH Biopharm Cyclically Adjusted PB Ratio Chart

TSH Biopharm Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.92 1.35 1.37 1.43 1.69

TSH Biopharm Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.43 1.60 1.93 1.63 1.69

Competitive Comparison of TSH Biopharm's Cyclically Adjusted PB Ratio

For the Drug Manufacturers - Specialty & Generic subindustry, TSH Biopharm's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


TSH Biopharm's Cyclically Adjusted PB Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, TSH Biopharm's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where TSH Biopharm's Cyclically Adjusted PB Ratio falls into.


;
;

TSH Biopharm Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

TSH Biopharm's Cyclically Adjusted PB Ratio for today is calculated as

Cyclically Adjusted PB Ratio=Share Price/ Cyclically Adjusted Book per Share
=49.90/36.30
=1.37

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

TSH Biopharm's Cyclically Adjusted Book per Share for the quarter that ended in Dec. 2024 is calculated as:

For example, TSH Biopharm's adjusted Book Value per Share data for the three months ended in Dec. 2024 was:

Adj_Book=Book Value per Share/CPI of Dec. 2024 (Change)*Current CPI (Dec. 2024)
=36.246/133.1571*133.1571
=36.246

Current CPI (Dec. 2024) = 133.1571.

TSH Biopharm Quarterly Data

Book Value per Share CPI Adj_Book
201503 26.478 99.621 35.391
201506 25.134 100.684 33.240
201509 29.466 100.392 39.083
201512 35.483 99.792 47.346
201603 34.152 100.470 45.263
201606 33.059 101.688 43.290
201609 33.294 101.861 43.523
201612 37.772 101.863 49.376
201703 37.614 102.862 48.692
201706 32.556 103.349 41.946
201709 30.673 104.136 39.221
201712 29.861 104.011 38.229
201803 32.285 105.290 40.830
201806 29.517 106.317 36.969
201809 29.497 106.507 36.878
201812 29.191 105.998 36.670
201903 30.575 107.251 37.960
201906 28.504 108.070 35.121
201909 29.147 108.329 35.827
201912 29.297 108.420 35.981
202003 27.437 108.902 33.548
202006 28.716 108.767 35.155
202009 28.831 109.815 34.959
202012 29.333 109.897 35.542
202103 29.611 111.754 35.282
202106 28.412 114.631 33.004
202109 28.443 115.734 32.725
202112 28.221 117.630 31.946
202203 28.535 121.301 31.324
202206 27.442 125.017 29.229
202209 27.674 125.227 29.427
202212 29.583 125.222 31.458
202303 28.344 127.348 29.637
202306 27.863 128.729 28.822
202309 28.127 129.860 28.841
202312 28.845 129.419 29.678
202403 33.247 131.776 33.595
202406 34.034 132.554 34.189
202409 36.532 133.029 36.567
202412 36.246 133.157 36.246

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


TSH Biopharm  (ROCO:8432) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


TSH Biopharm Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of TSH Biopharm's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


TSH Biopharm Business Description

Traded in Other Exchanges
N/A
Address
No.3-1, Park Street, 3rd Floor-1, Nangang District, Taipei, TWN, 115
TSH Biopharm Corp Ltd is engaged in sale of a variety of pharmaceuticals, chemical drugs and engaged in biotechnology services. The Company's revenue is earned domestically. It earns majority of its revenue from the sale of Lozenges.

TSH Biopharm Headlines

No Headlines